| scholarly article | Q13442814 |
| P50 | author | Issam El Naqa | Q57612481 |
| P2093 | author name string | Seth A Rosenthal | |
| W Robert Lee | |||
| Mark K Buyyounouski | |||
| Mark Ritter | |||
| Jeff Michalski | |||
| Colleen A F Lawton | |||
| Elizabeth O'Meara | |||
| Michael Seider | |||
| Cynthia Menard | |||
| P2860 | cites work | Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy | Q81410832 |
| The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification | Q33880046 | ||
| Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer | Q37013997 | ||
| Prostatic Lymphography | Q39533831 | ||
| Prostate cancer: anatomical and surgical considerations | Q41116361 | ||
| Extended pelvic lymphadenectomy for prostatic cancer | Q41574882 | ||
| Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial | Q44070350 | ||
| Validity of sentinel lymph node concept for patients with prostate cancer | Q44883460 | ||
| Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. | Q45930559 | ||
| Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. | Q45956742 | ||
| Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. | Q45996041 | ||
| Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer | Q46643781 | ||
| An Evaluation of Lymphangiography in Staging Carcinoma of the Prostate | Q66913830 | ||
| Is a limited lymph node dissection an adequate staging procedure for prostate cancer? | Q74493152 | ||
| Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis | Q77816739 | ||
| Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients | Q79764761 | ||
| Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer | Q80995021 | ||
| Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy | Q81296585 | ||
| Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of <10 ng/ml undergoing radical prostatectomy for prostate cancer? | Q81338026 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymph node | Q170758 |
| prostate cancer | Q181257 | ||
| radiation oncology | Q729267 | ||
| P304 | page(s) | 383-387 | |
| P577 | publication date | 2008-10-22 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer | |
| P478 | volume | 74 |
| Q50083626 | 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. |
| Q37776778 | A Review of the Clinical Evidence for Intensity-modulated Radiotherapy |
| Q42946766 | A dosimetric comparison of RapidArc and IMRT with hypofractionated simultaneous integrated boost to the prostate for treatment of prostate cancer |
| Q38399316 | A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. |
| Q41997352 | A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients |
| Q39456200 | ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. |
| Q48113934 | Accelerated tomotherapy delivery with TomoEdge technique |
| Q89599666 | Accuracy of automatic deformable structure propagation for high-field MRI guided prostate radiotherapy |
| Q34960367 | Adaptive radiotherapy in locally advanced prostate cancer using a statistical deformable motion model |
| Q36338035 | Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study |
| Q85822182 | Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only |
| Q41515385 | An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer. |
| Q45253735 | An overlap-volume-histogram based method for rectal dose prediction and automated treatment planning in the external beam prostate radiotherapy following hydrogel injection |
| Q59136739 | Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy |
| Q34139498 | Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial |
| Q40044229 | Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough? |
| Q46850619 | Automatic CT simulation optimization for radiation therapy: A general strategy |
| Q97644708 | Biological dose summation of intensity-modulated arc therapy and image-guided high-dose-rate interstitial brachytherapy in intermediate- and high-risk prostate cancer |
| Q42367839 | Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials. |
| Q42687909 | Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients |
| Q90018871 | Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting |
| Q42383361 | Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy |
| Q37601093 | Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer. |
| Q46062440 | Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer |
| Q36468039 | Contrast media use in radiation oncology: a prospective, controlled educational intervention study with retrospective analysis of patient outcomes |
| Q37053652 | Creation of RTOG compliant patient CT-atlases for automated atlas based contouring of local regional breast and high-risk prostate cancers |
| Q38931064 | Current role of spacers for prostate cancer radiotherapy |
| Q91757114 | Definition of fields margins for the optimized 2D radiotherapy of prostate carcinoma |
| Q37551255 | Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy |
| Q53064989 | Distribution of Prostate Sentinel Nodes: A SPECT-Derived Anatomic Atlas |
| Q38953316 | Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment. |
| Q42315718 | Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles. |
| Q82732209 | Effect of photon-beam energy on VMAT and IMRT treatment plan quality and dosimetric accuracy for advanced prostate cancer |
| Q38276603 | Evolution of hypofractionated accelerated radiotherapy for prostate cancer - the sunnybrook experience |
| Q38168635 | FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate. |
| Q36921562 | Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma |
| Q64272308 | Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy |
| Q28550852 | Harmonization of the Volume of Interest Delineation among All Eleven Radiotherapy Centers in the North of France |
| Q35835108 | Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial |
| Q37485229 | Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial |
| Q34462816 | Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial |
| Q59126113 | Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes |
| Q88007829 | Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial |
| Q91587813 | IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison |
| Q42379564 | Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial |
| Q42319014 | Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial |
| Q90523257 | Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis |
| Q52680980 | Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer. |
| Q90721074 | Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer |
| Q92801781 | Impact of daily soft-tissue image guidance to prostate on pelvic lymph node (PLN) irradiation for prostate patients receiving SBRT |
| Q82732225 | Impact of gantry rotation time on plan quality and dosimetric verification--volumetric modulated arc therapy (VMAT) vs. intensity modulated radiotherapy (IMRT) |
| Q47978964 | Improving postoperative radiotherapy following radical prostatectomy |
| Q41901038 | Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy |
| Q38974743 | Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant? |
| Q38109812 | Individualized image-based lymph node irradiation for prostate cancer |
| Q36942136 | Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study |
| Q37627132 | Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity |
| Q60311003 | Inter-fraction movements of the prostate and pelvic lymph nodes during IGRT |
| Q41101008 | Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients. |
| Q35000485 | Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy |
| Q50719203 | Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer. |
| Q92718589 | Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy |
| Q82448314 | Magnetic Resonance Lymphography–Guided Selective High-Dose Lymph Node Irradiation in Prostate Cancer |
| Q50072796 | Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial |
| Q99623715 | NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer |
| Q92186829 | New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer |
| Q31083823 | No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy |
| Q35789050 | OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer |
| Q39245161 | Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients |
| Q55399763 | PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. |
| Q90647382 | PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis |
| Q39491384 | Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage |
| Q38996907 | Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography |
| Q51840218 | Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging. |
| Q41312134 | Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy |
| Q89832045 | Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy |
| Q39804774 | Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. |
| Q64985980 | Postoperative elective pelvic nodal irradiation compared to prostate bed irradiation in locally advanced prostate cancer - a retrospective analysis of dose-escalated patients. |
| Q52589267 | Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. |
| Q92593356 | Pre-treatment 2D and 3D dosimetric verification of volumetric arc therapy. A correlation study between gamma index passing rate and clinical dose volume histogram |
| Q98938411 | Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach |
| Q89037253 | Prone Positioning on a Belly Board Decreases Rectal and Bowel Doses in Pelvic Intensity-Modulated Radiation Therapy (IMRT) for Prostate Cancer |
| Q34088596 | Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting |
| Q58079121 | Quantification of interobserver variability in image registration using conebeam CT for partial bladder radiotherapy - A Comparison between Lipiodol and Bladder Wall Surface |
| Q60918373 | Randomized prospective phase III trial of Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] |
| Q34247444 | Retrospective evaluation of dosimetric quality for prostate carcinomas treated with 3D conformal, intensity modulated and volumetric modulated arc radiotherapy |
| Q52987643 | Scanned ion beam therapy for prostate carcinoma: Comparison of single plan treatment and daily plan-adapted treatment. |
| Q53174206 | See the unseen: Mesorectal lymph node metastases in prostate cancer. |
| Q40990362 | Sentinel lymph node imaging guided IMRT for prostate cancer: Individualized pelvic radiation therapy versus RTOG guidelines |
| Q50179081 | Simultaneous integrated boost (SIB) of the parametrium and cervix in radiotherapy for uterine cervical carcinoma: a dosimetric study using a new alternative approach. |
| Q45342738 | Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer |
| Q40921939 | Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy |
| Q39198013 | Spacer application for prostate cancer radiation therapy |
| Q41830239 | Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT. |
| Q38563492 | Technology assessment of automated atlas based segmentation in prostate bed contouring. |
| Q50186825 | The Utility of PET/CT in External Radiation Therapy Planning of Prostate Cancer. |
| Q34433023 | The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer |
| Q36331821 | The effect of photon energy on intensity-modulated radiation therapy (IMRT) plans for prostate cancer |
| Q37939464 | The role of surgery in high-risk localised prostate cancer |
| Q37367034 | Transformation of physical DVHs to radiobiologically equivalent ones in hypofractionated radiotherapy analyzing dosimetric and clinical parameters: a practical approach for routine clinical practice in radiation oncology |
| Q43410693 | Treatment planning after hydrogel injection during radiotherapy of prostate cancer |
| Q53098000 | Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. |
| Q41897302 | Whole-pelvic volumetric-modulated arc therapy for high-risk prostate cancer: treatment planning and acute toxicity |
Search more.